Insights

Why DBV Technologies Was a Big Winner on Wednesday

What happened
Shares of the unique biotech DBV Technologies (NASDAQ: DBVT) surged nearly 20% higher on Wednesday, far outpacing many peer stocks. That’s because the company had some very encouraging news to impart about its key pipeline drug.
So what
DBV is developing a patch treatment for peanut allergies called Viaskin Peanut, and on Wednesday, it published an update about the clinical testing of this product.
DBV said that the results of the latest Viaskin Peanut phase 3 trial — on children 1 to 3 years old — indicate that 67% of respondents “demonstrated a statistically significant treatment effect” from the patch. This compared favorably to the nearly 34% of patients administered a placebo. The biotech added that the safety results were “generally consistent” with those of prior clinical trials in children aged four and older.
Not only are the results encouraging and significant, but they were also produced in an age group that seems to be ideal for treatment.
In its press release, DBV quoted the chairman of its scientific advisory board Hugh Sampson as saying that “Most peanut-allergic children are diagnosed between 1 to 3 years of age; however, there are currently no FDA-approved therapies for this age group. Furthermore, there is growing evidence on the benefits of treatment from a younger age.”
Now what
This represents a positive reversal of fortune for DBV. Viaskin Peanut was rejected by the Food and Drug Administration, mainly on concerns about how the patch’s contents were absorbed by the patient. As Viaskin in various forms is by far the biotech company’s most significant product, these new clinical trial results are more than encouraging. 
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. –

What happened

Shares of the unique biotech DBV Technologies (NASDAQ: DBVT) surged nearly 20% higher on Wednesday, far outpacing many peer stocks. That’s because the company had some very encouraging news to impart about its key pipeline drug.

So what

DBV is developing a patch treatment for peanut allergies called Viaskin Peanut, and on Wednesday, it published an update about the clinical testing of this product.

DBV said that the results of the latest Viaskin Peanut phase 3 trial — on children 1 to 3 years old — indicate that 67% of respondents “demonstrated a statistically significant treatment effect” from the patch. This compared favorably to the nearly 34% of patients administered a placebo. The biotech added that the safety results were “generally consistent” with those of prior clinical trials in children aged four and older.

Not only are the results encouraging and significant, but they were also produced in an age group that seems to be ideal for treatment.

In its press release, DBV quoted the chairman of its scientific advisory board Hugh Sampson as saying that “Most peanut-allergic children are diagnosed between 1 to 3 years of age; however, there are currently no FDA-approved therapies for this age group. Furthermore, there is growing evidence on the benefits of treatment from a younger age.”

Now what

This represents a positive reversal of fortune for DBV. Viaskin Peanut was rejected by the Food and Drug Administration, mainly on concerns about how the patch’s contents were absorbed by the patient. As Viaskin in various forms is by far the biotech company’s most significant product, these new clinical trial results are more than encouraging. 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Free Share Allocation Reward Levels

STARTER

Class
$ 2,500 Deposit & Trade
  • REWARD^
  • 1 x Marathon Oil Corporation (NYSE:MRO)

ECONOMY

Basic
$ 5,000 Deposit & Trade
  • REWARD^
  • 1 x Pfizer Inc (NASDAQ:PFE)

ECONOMY

Standard
$ 10,000 Deposit & Trade
  • REWARD^
  • 1 x Amazon.com Inc (NASDAQ:AMZN)

ECONOMY

Plus
$ 25,000 Deposit & Trade
  • REWARD^
  • 2 x Apple Inc (NASDAQ:AAPL)
POPULAR

BUSINESS

Class
$ 50,000 Deposit & Trade
  • REWARD^
  • 4 x Apple Inc (NASDAQ:AAPL)

FIRST

Class
$ 150,000 Deposit & Trade
  • REWARD CHOICES^
  • 12 x Apple Inc (NASDAQ:AAPL)
  • 2 x Tesla (NASDAQ:TSLA)
^Please refer to the Free Share Promotion Terms and Conditions for details.

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex Securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here To Get Started
FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here For More Info